Literature DB >> 22813089

The return of rainbow diet pills.

Pieter A Cohen1, Alberto Goday, John P Swann.   

Abstract

The US Food and Drug Administration (FDA) has recently warned consumers about the risks of weight loss supplements adulterated with multiple pharmaceutical agents. Some of these supplements combine potent anorectics, such as amphetamines derivatives, with benzodiazepines, beta-blockers, and other medications to suppress the anorectics' adverse effects. These weight loss supplements represent the most recent generation of rainbow diet pills, named for their bright and varied colors, which date back more than 70 years. Beginning in the 1940s, several US pharmaceutical firms aggressively promoted rainbow pills to physicians and patients. By the 1960s the pills had caused dozens of deaths before the FDA began removing them from the US market. We used a variety of original resources to trace these deadly pills from their origins in the United States to their popularity in Spain and Brazil to their reintroduction to the United States as weight loss dietary supplements.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22813089      PMCID: PMC3482033          DOI: 10.2105/AJPH.2012.300655

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  12 in total

1.  Dependence on the Brazilian diet pill: a case report.

Authors:  Benjamin R Smith; Pieter A Cohen
Journal:  Am J Addict       Date:  2010 May-Jun

2.  Anorectics on trial: a half century of federal regulation of prescription appetite suppressants.

Authors:  Eric Colman
Journal:  Ann Intern Med       Date:  2005-09-06       Impact factor: 25.391

3.  Imported compounded diet pill use among Brazilian women immigrants in the United States.

Authors:  Pieter A Cohen; Danny McCormick; Carolyn Casey; Glen F Dawson; Karen A Hacker
Journal:  J Immigr Minor Health       Date:  2007-12-09

4.  Redotex ingestions reported to Texas poison centers.

Authors:  Mathias B Forrester
Journal:  Hum Exp Toxicol       Date:  2010-02-17       Impact factor: 2.903

5.  Drug abuse control under FDA, 1938-1968.

Authors:  J P Swann
Journal:  Public Health Rep       Date:  1997 Jan-Feb       Impact factor: 2.792

6.  Reducing pills and digitalis intoxication.

Authors: 
Journal:  JAMA       Date:  1968-10-28       Impact factor: 56.272

7.  Use of a pharmaceutically adulterated dietary supplement, Pai You Guo, among Brazilian-born women in the United States.

Authors:  Pieter A Cohen; Carly Benner; Danny McCormick
Journal:  J Gen Intern Med       Date:  2011-08-16       Impact factor: 5.128

8.  Use of anorectic amphetamine-like drugs by Brazilian women.

Authors:  Solange A Nappo; Ricardo Tabach; Ana Regina Noto; José Carlos F Galduróz; Elisaldo Araújo Carlini
Journal:  Eat Behav       Date:  2002

9.  Imported fenproporex-based diet pills from Brazil: a report of two cases.

Authors:  Pieter A Cohen
Journal:  J Gen Intern Med       Date:  2009-03       Impact factor: 5.128

10.  [Iatrogenic hyperthyroidism. Report of an outbreak].

Authors:  A Goday; A Recasens; M Méndez; V Yetano; P Guirado
Journal:  Med Clin (Barc)       Date:  1995-11-18       Impact factor: 1.725

View more
  9 in total

Review 1.  Signaling pathways in obesity: mechanisms and therapeutic interventions.

Authors:  Xue Wen; Bohan Zhang; Beiyi Wu; Haitao Xiao; Zehua Li; Ruoyu Li; Xuewen Xu; Tao Li
Journal:  Signal Transduct Target Ther       Date:  2022-08-28

2.  Suspected adverse reaction to compounded preparations prescribed for weight loss: two cases of cerebral venous thrombosis.

Authors:  Beatrice Mainoli; Mariana Carvalho Dias; Patricia Canhão; Mário Miguel Rosa
Journal:  BMJ Case Rep       Date:  2020-03-31

3.  Russian roulette with unlicensed fat-burner drug 2,4-dinitrophenol (DNP): evidence from a multidisciplinary study of the internet, bodybuilding supplements and DNP users.

Authors:  Andrea Petróczi; Jorge A Vela Ocampo; Iltaf Shah; Carl Jenkinson; Rachael New; Ricky A James; Glenn Taylor; Declan P Naughton
Journal:  Subst Abuse Treat Prev Policy       Date:  2015-10-14

Review 4.  Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review.

Authors:  Igho J Onakpoya; Carl J Heneghan; Jeffrey K Aronson
Journal:  BMC Med       Date:  2016-11-29       Impact factor: 8.775

5.  Would You Use It With a Seal of Approval? Important Attributes of 2,4-Dinitrophenol (2,4-DNP) as a Hypothetical Pharmaceutical Product.

Authors:  Emma E Bleasdale; Sam N Thrower; Andrea Petróczi
Journal:  Front Psychiatry       Date:  2018-04-20       Impact factor: 4.157

Review 6.  Anti-obesity drug discovery: advances and challenges.

Authors:  Timo D Müller; Matthias Blüher; Matthias H Tschöp; Richard D DiMarchi
Journal:  Nat Rev Drug Discov       Date:  2021-11-23       Impact factor: 112.288

7.  From leptin to lasers: the past and present of mouse models of obesity.

Authors:  Joshua R Barton; Adam E Snook; Scott A Waldman
Journal:  Expert Opin Drug Discov       Date:  2021-01-29       Impact factor: 7.050

Review 8.  Safety and efficacy of fenproporex for obesity treatment: a systematic review.

Authors:  Francisco José Roma Paumgartten; Sabrina Schaaf Teixeira Costa Pereira; Ana Cecilia Amado Xavier de Oliveira
Journal:  Rev Saude Publica       Date:  2016-05-24       Impact factor: 2.106

Review 9.  Gut hormone polyagonists for the treatment of type 2 diabetes.

Authors:  Sara J Brandt; Anna Götz; Matthias H Tschöp; Timo D Müller
Journal:  Peptides       Date:  2018-02       Impact factor: 3.750

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.